试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae
编号:NCT04760665登记状态:提前终止企业 / 申办者:Maimónides Biomedical Research Institute of Córdoba
药物 / 成分:Fecal microbiota transplantation、Placebo
登记的停止原因(原文):lack of elegible population
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
编号:NCT04933617登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Rituximab、Etoposide、Copanlisib、Cyclophosphamide
登记的停止原因(原文):The study was terminated early because copanlisib was removed from the market by the Food and Drug Administration (FDA) and the manufacturer.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
编号:NCT05077969登记状态:提前终止企业 / 申办者:Leidos Life Sciences
药物 / 成分:Famotidine、Celecoxib、Placebo
登记的停止原因(原文):Low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
[18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects
编号:NCT05564429登记状态:提前终止企业 / 申办者:National Institute of Mental Health (NIMH)
药物 / 成分:18F-SF12051
登记的停止原因(原文):due to futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
编号:NCT05769959登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:RO7515629、tocilizumab
登记的停止原因(原文):Sponsor decision (not related to safety, efficacy or quality).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-08
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
编号:NCT02295722登记状态:提前终止企业 / 申办者:AHS Cancer Control Alberta
药物 / 成分:Gemcitabine、Melphalan、ASCT
登记的停止原因(原文):It did not show a significant benefit to justify completing the full target accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-08
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
编号:NCT04343248登记状态:提前终止企业 / 申办者:Romark Laboratories L.C.
药物 / 成分:Nitazoxanide、Placebo、Vitamin Super B-Complex
登记的停止原因(原文):Study recruitment was halted prematurely as widespread vaccination of the study population made completion infeasible.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-08
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
编号:NCT04656262登记状态:提前终止企业 / 申办者:Istituto Oncologico Veneto IRCCS
药物 / 成分:Cyclophosphamide、Doxorubicin
登记的停止原因(原文):enrollment too slow to reach the target in a reasonable time frame
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-08
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
编号:NCT05105412登记状态:提前终止企业 / 申办者:National Health Research Institutes, Taiwan
药物 / 成分:Lenalidomide and Gemcitabine (Dose level 11)、Lenalidomide and Gemcitabine (Dose level 21)、Lenalidomide and Gemcitabine (Dose level 31)、Lenalidomide and Gemcitabine (Dose level 41)
登记的停止原因(原文):The resolution of DSMB
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-05
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
编号:NCT02801617登记状态:提前终止企业 / 申办者:Laboratorios Sophia S.A de C.V.
药物 / 成分:PRO-067、GAAP Ofteno®
登记的停止原因(原文):expiration time limit of recruitment
查看官方原始记录 ↗